1. Home
  2. HMR vs PRPO Comparison

HMR vs PRPO Comparison

Compare HMR & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HMR

Heidmar Maritime Holdings Corp.

HOLD

Current Price

$0.90

Market Cap

49.3M

ML Signal

HOLD

Logo Precipio Inc.

PRPO

Precipio Inc.

HOLD

Current Price

$28.50

Market Cap

44.4M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMR
PRPO
Founded
1984
N/A
Country
Greece
United States
Employees
57
N/A
Industry
Marine Transportation
Biotechnology: Laboratory Analytical Instruments
Sector
Consumer Discretionary
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
49.3M
44.4M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
HMR
PRPO
Price
$0.90
$28.50
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$5.00
N/A
AVG Volume (30 Days)
39.4K
12.0K
Earning Date
03-24-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.15
EPS
N/A
N/A
Revenue
N/A
$24,049,000.00
Revenue This Year
$64.04
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.77
52 Week Low
$0.76
$5.19
52 Week High
$3.12
$29.53

Technical Indicators

Market Signals
Indicator
HMR
PRPO
Relative Strength Index (RSI) 53.78 58.34
Support Level $0.87 $22.96
Resistance Level $0.96 $28.76
Average True Range (ATR) 0.05 1.79
MACD 0.01 0.15
Stochastic Oscillator 66.47 87.69

Price Performance

Historical Comparison
HMR
PRPO

About HMR Heidmar Maritime Holdings Corp.

Heidmar Maritime Holdings Corp is an asset-light tanker pool, and commercial and technical management company. The company is a fast-growing tanker pool company engaged in the commercial management and chartering of crude oil and refined petroleum product tankers. The company has also recently expanded its business to offer pool management of dry bulk vessels and technical management. The company generates maximum revenue from Singapore.

About PRPO Precipio Inc.

Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.

Share on Social Networks: